Autor: |
Karlström, Sofia, Nordvall, Gunnar, Sohn, Daniel, Hettman, Andreas, Turek, Dominika, Åhlin, Kristofer, Kers, Annika, Claesson, Martina, Slivo, Can, Lo-Alfredsson, Yvonne, Petersson, Carl, Bessidskaia, Galina, Svensson, Per H., Rein, Tobias, Jerning, Eva, Malmberg, Åsa, Ahlgen, Charlotte, Ray, Colin, Vares, Lauri, Ivanov, Vladimir, Johansson, Rolf |
Zdroj: |
Journal of Medicinal Chemistry; 20240101, Issue: Preprints |
Abstrakt: |
We have developed two parallel series, A and B, of CX3CR1 antagonists for the treatment of multiple sclerosis. By modifying the substituents on the 7-amino-5-thio-thiazolo[4,5-d]pyrimidine core structure, we were able to achieve compounds with high selectivity for CX3CR1 over the closely related CXCR2 receptor. The structure–activity relationships showed that a leucinol moiety attached to the core-structure in the 7-position together with α-methyl branched benzyl derivatives in the 5-position displayed promising affinity, and selectivity as well as physicochemical properties, as exemplified by compounds 18aand 24h. We show the preparation of the first potent and selective orally available CX3CR1 antagonists. |
Databáze: |
Supplemental Index |
Externí odkaz: |
|